June 10 Allergan Inc's "inaccurate and
misleading statements" and unsupported arguments about Valeant
Pharmaceuticals Inc leaves Valeant no choice but to
take its $53 billion takeover offer directly to Allergan
shareholders, Valeant said on Tuesday.
Allergan's board has been unwilling to meet with Valeant,
which it must do to properly gauge the value of Valeant's offer,
spokeswoman Laurie Little said in a statement. Allergan rejected
Valeant's most recent offer earlier in the day.
(Reporting by Rod Nickel in Winnipeg, Manitoba)